CLINICAL PHASE-I STUDY OF NA2B12H11SH (BSH) IN PATIENTS WITH MALIGNANT GLIOMA AS PRECONDITION FOR BORON NEUTRON-CAPTURE THERAPY (BNCT)

被引:69
|
作者
HARITZ, D
GABEL, D
HUISKAMP, R
机构
[1] UNIV BREMEN,DEPT CHEM,W-2800 BREMEN,GERMANY
[2] NETHERLANDS ENERGY RES FDN,ECN,1755 ZG PETTEN,NETHERLANDS
关键词
BNCT; GLIOBLASTOMA MULTIFORME; BORON DETERMINATION TECHNIQUES; BSH PHARMACOKINETICS; BSH BIODISTRIBUTION; BSH TOXICOLOGY;
D O I
10.1016/0360-3016(94)90492-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Within the European collaboration on boron neutron capture therapy (BNCT), a clinical Phase I study is being carried out to establish BNCT as an alternative treatment modality for malignant glioma (WHO III/IV). Data about the pharmacokinetics, biodistribution and toxicity of the boron compound Na2B12H11SH (BSH) are of great importance to avoid radiation damage of healthy tissue and to deliver a sufficient radiation dose. Methods and Materials: Twenty four patients suffering from a glioblastoma multiforme entered the study to date, infused with a maximum concentration of up to 50 mg BSH/kg. Boron concentration measurements in tissues, urine, and blood were carried out, using inductively coupled plasma-atomic spectroscopy (ICP-AES) and quantitative neutron capture radiography (QNCR). A cross-calibration of these boron determination techniques was carried out. Results: In tumor tissue, confirmed by histopathology of small biopsies, we found a consistently high but heterogeneous boron uptake. Necrotic parts contain much lower amounts of boron; normal brain tissue has shown no significant uptake. In skin, bone, muscle, and dura mater only small amounts of boron were found. In blood samples, we found biphasic kinetics, but with variations of the half-lives from patient to patient. The compound is mainly excreted through the urine, but an additional entero-hepatic pathway can be demonstrated. Systematic investigations revealed no toxic side effect of the intravenously administered BSH. Comparable data were obtained by using ICP-AES and QNCR for boron concentration measurements. Conclusion: Taking into account the radiobiological considerations of the neutron beam source, we found promising facts that BNCT could be a useful irradiation method for highly malignant brain tumors. Favorable amounts of the boron compound BSH mere found in tumor tissue, whereas healthy brain tissue has shown no significant uptake.
引用
收藏
页码:1175 / 1181
页数:7
相关论文
共 37 条
  • [21] Quality control of Na2B12H11SH, a drug for boron neutron capture therapy in eortc trial 11961
    Gabel, D
    Touw, D
    Stecher-Rasmussen, F
    Huiskamp, R
    Sauerwein, W
    FRONTIERS IN NEUTRON CAPTURE THERAPY, VOLS 1 AND 2, 2001, : 257 - 260
  • [22] Quality control of Na2B12H11SH, a drug for boron neutron capture therapy in EORTC trial 11961
    Gabel, D
    Touw, D
    Stecher-Rasmussen, F
    Huiskamp, R
    Sauerwein, W
    ANNALS OF ONCOLOGY, 1998, 9 : 129 - 129
  • [23] Determination of BSH (Na2B12H11SH) absorbed in tumor tissue
    Nakagawa, Y
    Pooh, K
    Sone, M
    Kageji, T
    Nakaichi, M
    Takahashi, H
    Amemiya, K
    Gabel, D
    FRONTIERS IN NEUTRON CAPTURE THERAPY, VOLS 1 AND 2, 2001, : 933 - 937
  • [24] Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to malignant glioma by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT)
    Doi, A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 345 - 345
  • [25] Membrane binding of Na2B12H1SH (BSH) with phosphatidylcholine in boron neutron capture therapy
    Kageji, T
    Nagahiro, S
    Matsumoto, K
    Otersen, B
    Gabel, D
    Nakagawa, Y
    FRONTIERS IN NEUTRON CAPTURE THERAPY, VOLS 1 AND 2, 2001, : 1039 - 1044
  • [26] Phase I study of boron neutron capture therapy (BNCT) using accelerator BNCT system for the recurrent malignant glioma
    Kawabata, Shinji
    Hitamatsu, Ryo
    Matsushita, Yoko
    Fujishiro, Takahiro
    Furuse, Motomasa
    Kondo, Natsuko
    Kuroiwa, Toshihiko
    Ono, Koji
    CANCER SCIENCE, 2018, 109 : 454 - 454
  • [27] The compound factor of Na2B12H11SH and the relative biological effectiveness of recoil protons for neurological damage in boron neutron capture therapy
    Gabel, D
    Philipp, KHI
    Huiskamp, R
    CANCER NEUTRON CAPTURE THERAPY, 1996, : 815 - 821
  • [28] Spectromicroscopy of boron in human glioblastomas following administration of Na2B12H11SH
    Gilbert, B
    Perfetti, L
    Fauchoux, O
    Redondo, J
    Baudat, PA
    Andres, R
    Neumann, M
    Steen, S
    Gabel, D
    Mercanti, D
    Ciotti, MT
    Perfetti, P
    Margaritondo, G
    De Stasio, G
    PHYSICAL REVIEW E, 2000, 62 (01): : 1110 - 1118
  • [29] DISTRIBUTION OF BORON IN 2 (B12H11SH)2--INFUSED PATIENTS WITH MALIGNANT GLIOMA
    SLATKIN, DN
    FINKEL, GC
    MICCA, PL
    LASTER, BH
    POLETTI, CE
    SWEET, WH
    STRAHLENTHERAPIE UND ONKOLOGIE, 1989, 165 (2-3): : 224 - 246
  • [30] NEUTRON-INDUCED TRACK ETCH AUTORADIOGRAPHY OF THE THERAPEUTIC COMPOUND (NA2B12H11SH)-B-10
    KIRSCH, JE
    BROWNELL, GL
    MEDICAL PHYSICS, 1981, 8 (05) : 736 - 736